Highlights
IIA supported (ever)1 patentProfile claimed by owner
About
Cancer Drugs to Bypass Resistance Mutations
Novitero is a computational drug design and development company working to enable precise and effective cancer treatments. The companys technology is designed to proactively combat cancer by previewing its mutational activities and overcoming its resistance to therapies. Noviteros goal is to predict and bypass the potential mutations that cancer may adopt to resist therapies. The company uses its computational technologies to predict the mutational fingerprints implicated in drug resistance to various therapeutic targets. It then designs, validates, and out-licenses new drugs that bypass these mutations.
Identity
| Name | Novitero |
|---|---|
| Slug | novitero |
| Type / kind | startup |
| Crunchbase ID | novitero |
| Source _id | agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgN7ulJgLDA |
Status
| Status | inactive |
|---|---|
| Status reason | Non Active, Jan 2021 ceased to operate |
| Last update | 2026-05-17 |
Location
| HQ country code | IL |
|---|---|
| HQ region/district | Center District |
| HQ city | Ness Ziona |
| HQ address | Lotus Street 22, Ness Ziona, Israel |
Web & social
| Website | http://www.novitero.com/ |
|---|
Classifications
Primary sector Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
BiologicalsMolecules
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticalsBiotechnology
Business models
B2B
Tags
drug-designdrug-discoverytargeted-cancer-therapycancer-therapypersonalizationpharma-companiesbioinformatics
Funding
| Total raised | $50K |
|---|---|
| Current stage | Pre-Funding |
Raw source document
Show full JSON (0 KB)
{
"0": "s",
"1": "l",
"2": "i",
"3": "m",
"4": "p",
"5": "a",
"6": "g",
"7": "e",
"8": "s",
"9": "_",
"10": "i",
"11": "m",
"12": "p",
"13": "o",
"14": "r",
"15": "t"
}